{"id":"https://openalex.org/W2762299698","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps3091","title":"A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.","display_name":"A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2762299698","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps3091","mag":"2762299698"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.tps3091","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps3091","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps3091","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034434819","display_name":"Martin Wermke","orcid":"https://orcid.org/0000-0002-4844-4087","observed_orcids":["https://orcid.org/0000-0002-4844-4087"]},"institutions":[{"id":"https://openalex.org/I4210162051","display_name":"University Hospital Carl Gustav Carus","ror":"https://ror.org/04za5zm41","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210162051"]},{"id":"https://openalex.org/I78650965","display_name":"Technische Universit\u00e4t Dresden","ror":"https://ror.org/042aqky30","country_code":"DE","type":"education","lineage":["https://openalex.org/I78650965"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin Wermke","raw_affiliation_strings":["Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany;","institution_ids":["https://openalex.org/I4210162051","https://openalex.org/I78650965"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014653989","display_name":"Helmuth Schmidt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Helmuth Schmidt","raw_affiliation_strings":["Cellex GmbH, Cologne, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cellex GmbH, Cologne, Germany;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112856724","display_name":"Hildegard Nolte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I197323543","display_name":"Johannes Gutenberg University Mainz","ror":"https://ror.org/023b0x485","country_code":"DE","type":"education","lineage":["https://openalex.org/I197323543"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hildegard Nolte","raw_affiliation_strings":["Johannes Gutenberg Universit\u00e4t, Mainz, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johannes Gutenberg Universit\u00e4t, Mainz, Germany;","institution_ids":["https://openalex.org/I197323543"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033334588","display_name":"Sebastian Ochsenreither","orcid":"https://orcid.org/0000-0001-6024-4312","observed_orcids":["https://orcid.org/0000-0001-6024-4312"]},"institutions":[{"id":"https://openalex.org/I4392738228","display_name":"Stiftung Charit\u00e9","ror":"https://ror.org/016rf0n60","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4392738228","https://openalex.org/I7877124"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Sebastian Ochsenreither","raw_affiliation_strings":["Department of Hematology and Medical Oncology, Charit\u00e9, CBF, Berlin, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical Oncology, Charit\u00e9, CBF, Berlin, Germany;","institution_ids":["https://openalex.org/I4392738228","https://openalex.org/I7877124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049679213","display_name":"Jonathan Back","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121530","display_name":"Glenmark Pharmaceuticals (Switzerland)","ror":"https://ror.org/024s32d89","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210121530","https://openalex.org/I4210131532"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Jonathan Back","raw_affiliation_strings":["Glenmark Pharmaceuticals, La Chaux-De-Fonds, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals, La Chaux-De-Fonds, Switzerland;","institution_ids":["https://openalex.org/I4210121530"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112393964","display_name":"Yacine Salhi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yacine Salhi","raw_affiliation_strings":["Glenmark Pharmaceuticals, Hertfordshire, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals, Hertfordshire, United Kingdom;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048957048","display_name":"Eliel Bayever","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eliel Bayever","raw_affiliation_strings":["Merrimack Pharmaceuticals, Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merrimack Pharmaceuticals, Inc., Cambridge, MA;","institution_ids":["https://openalex.org/I4210124791"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"TPS3091","last_page":"TPS3091"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.8227999806404114,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.8227999806404114,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.15600000321865082,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-cancer","display_name":"HER2-positive cancer","score":0.8799999952316284},{"id":"https://openalex.org/keywords/cd3e","display_name":"CD3\u03b5","score":0.675000011920929},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8090000152587891},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.890999972820282},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.765999972820282},{"id":"https://openalex.org/keywords/echocardiographic-monitoring","display_name":"echocardiographic monitoring","score":0.7940000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6779999732971191},{"id":"https://openalex.org/keywords/adaptive-immune-response","display_name":"adaptive immune response","score":0.6370000243186951},{"id":"https://openalex.org/keywords/trastuzumab-resistance","display_name":"trastuzumab resistance","score":0.7979999780654907},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6269999742507935}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8708877563476562},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.654364287853241},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5907374620437622},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5352723002433777},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5013971328735352},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.449614942073822},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.42796817421913147},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4271726906299591},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.41044723987579346},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.3550589382648468},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24934318661689758}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.tps3091","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps3091","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps3091","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2794322099","https://openalex.org/W2588297494","https://openalex.org/W2898147700","https://openalex.org/W2905298009","https://openalex.org/W2587850084","https://openalex.org/W2889732299","https://openalex.org/W2567662940","https://openalex.org/W2789422517","https://openalex.org/W4254108101","https://openalex.org/W2559870804"],"abstract_inverted_index":{"TPS3091":[0],"Background:":[1],"GBR":[2,38,70,107,142,183,188,204,256],"1302,":[3],"a":[4,163,171,246],"bispecific":[5],"antibody":[6],"based":[7],"on":[8,258],"Glenmark\u2019s":[9],"BEAT":[10],"platform,":[11],"is":[12,126,139,144],"designed":[13],"to":[14,22,74,84,92,222,234],"recruit":[15],"cytotoxic":[16],"T-cells":[17],"(independent":[18],"of":[19,34,44,61,106,119,157,182,187,196,239,255],"their":[20],"specificity)":[21],"HER2-positive":[23,45,113,131],"cancer":[24,47],"cells":[25,48],"where":[26],"they":[27],"are":[28],"activated":[29],"by":[30,53],"the":[31,35,62,69,89,158,191,220,235,259],"CD3e-specific":[32],"domain":[33],"molecule.":[36],"Preclinically,":[37],"1302":[39,71,108,143,189,205,257],"has":[40],"demonstrated":[41],"potent":[42],"killing":[43],"human":[46],"(HER2":[49],"3+":[50,95],"or":[51,210],"2+":[52],"IHC":[54],"HercepTest),":[55],"as":[56,58,227,229],"well":[57,228],"growth":[59],"suppression":[60],"trastuzumab-resistant":[63],"cell":[64,97],"line":[65],"JIMT-1.":[66],"In":[67],"contrast,":[68],"concentration":[72,90],"required":[73],"kill":[75,93],"primary":[76],"cardiomyocytes":[77],"with":[78,112,129,190],"normal":[79],"HER2":[80,94],"levels":[81,271],"was":[82],"up":[83],"1000":[85],"times":[86],"greater":[87],"than":[88],"needed":[91],"tumor":[96],"lines.":[98],"This":[99],"study":[100,124,244],"will":[101,216,263],"determine":[102],"safety":[103,230],"and":[104,185,194,231,249,269],"tolerability":[105],"monotherapy":[109],"in":[110,149,272],"subjects":[111,169,202,218],"cancers.":[114],"Methods:":[115],"Part":[116,213],"1":[117,123],"(dose-finding)":[118],"this":[120,243],"ongoing":[121],"phase":[122],"(NCT02829372)":[125],"enrolling":[127],"adults":[128],"progressing":[130],"solid":[132],"tumors":[133],"for":[134],"which":[135],"no":[136],"standard":[137,172],"treatment":[138,206],"available.":[140],"Intravenous":[141],"given":[145],"every":[146],"2":[147,214],"weeks":[148],"28-day":[150],"cycles":[151],"at":[152,219,267],"escalating":[153],"doses":[154],"(Table).":[155],"Each":[156],"first":[159],"4":[160],"cohorts":[161,167],"includes":[162],"single":[164],"subject;":[165],"subsequent":[166],"enroll":[168],"using":[170],"3+3":[173],"design.":[174],"Primary":[175],"endpoints":[176],"are:":[177],"maximum":[178],"tolerated":[179],"dose":[180],"(MTD)":[181],"1302;":[184],"relationship":[186],"incidence,":[192],"nature,":[193],"intensity":[195],"adverse":[197],"events.":[198],"After":[199],"Cycle":[200],"1,":[201],"continue":[203],"until":[207],"disease":[208],"progression":[209],"unacceptable":[211],"toxicity.":[212],"(expansion)":[215],"treat":[217],"MTD":[221],"further":[223],"evaluate":[224],"anti-tumor":[225],"activity,":[226],"pharmacokinetics.":[232],"Due":[233],"known":[236],"cardiotoxic":[237],"potential":[238],"classic":[240],"HER2-targeting":[241],"strategies,":[242],"incorporates":[245],"rigorous":[247],"serological":[248,270],"echocardiographic":[250],"surveillance":[251],"schedule.":[252],"The":[253],"effects":[254],"adaptive":[260],"immune":[261],"system":[262],"also":[264],"be":[265],"studied":[266],"cellular":[268],"translational":[273],"research.":[274],"Clinical":[275],"trial":[276],"information:":[277],"NCT02829372.":[278],"[Table:":[279],"see":[280],"text]":[281]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-22T18:32:59.640997","created_date":"2017-10-20T00:00:00"}